药明合联(02268)于2026年4月8日发布公告指出，公司自2026年4月1日至4月8日期间，因多次行使其首次公开发售前购股权计划，共合计发行1,507,353股普通股，占公司此前已发行股本约0.12%。本次发行价格区间为每股1.8024港元至7.501港元。
公告显示，本次变动使公司已发行股本由1,258,835,897股增至1,260,343,250股，库藏股数维持为0股。公司同时确认，前述股份发行已获董事会正式授权，并遵照所有适用的上市规则和相关法律法规进行。公告由执行董事、首席财务官兼公司秘书席晓捷签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.